Skip to main content
. Author manuscript; available in PMC: 2024 Nov 18.
Published in final edited form as: Lancet Oncol. 2023 Sep 1;24(9):1018–1028. doi: 10.1016/S1470-2045(23)00335-2

Figure 2. Survival from randomisation until June 30, 2020, of women with tubo-ovarian high-grade serous cancer diagnosed between randomisation and censorship (Dec 31, 2014) in the no screening and multimodal screening groups.

Figure 2

(A) Denominator is women diagnosed with high-grade serous cancer. (B) Denominator is all eligible randomised women. Shaded areas are 95% CI.